By Fineline Cube Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196; HKG: 2196) announced that China’s National Medical Products Administration (NMPA) has granted approval for a supplemental New Drug Application (sNDA) for Fumaining (luvometinib), extending its use to pediatric and adolescent patients aged 2 years and older with relapsed or refractory Langerhans cell histiocytosis (LCH) following systemic therapy.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Supplemental New Drug Application (sNDA) |
| Product | Fumaining (luvometinib) – selective MEK1/2 inhibitor |
| New Indication | Pediatric/adolescent LCH (≥2 years, relapsed/refractory post-systemic therapy) |
| Approval Date | 16 Jun 2026 |
| Existing Indications | Adult LCH/histiocytic neoplasms; pediatric NF1 with symptomatic inoperable PN |
Drug Profile & Mechanism of Action
- Molecule: Luvometinib – highly selective MEK1/2 inhibitor
- Target: MEK1/2 kinases in the RAS/RAF/MEK/ERK signaling pathway
- Innovation: First MEK inhibitor approved in China for pediatric LCH; addresses significant unmet need in rare histiocytic disorders
- Development Status: Additional sNDA for adult NF1 patients with symptomatic inoperable PN accepted by NMPA with priority review designation
Clinical Development Pipeline
| Indication | Phase | Population | Status |
|---|---|---|---|
| Pediatric Low-Grade Glioma | III | Children with progressive disease | Ongoing |
| Extracranial Arteriovenous Malformation | II | Patients with symptomatic lesions | Active |
| KRAS-Mutant Advanced NSCLC | II | Adults with confirmed KRAS mutations | Recruiting |
| Adult NF1 with Inoperable PN | – | Symptomatic patients | sNDA under priority review |
The expanded approval for pediatric LCH builds on luvometinib’s established safety profile and demonstrates Fosun Pharma’s commitment to addressing rare diseases with high unmet medical needs across diverse age groups.
Market Impact & Strategic Significance
- Rare Disease Focus: LCH affects approximately 4–9 per million children annually in China, with limited treatment options for relapsed/refractory cases
- Franchise Expansion: This approval represents the third indication for Fumaining in China, strengthening Fosun’s position in targeted oncology therapies
- Competitive Landscape: Luvometinib joins a select group of MEK inhibitors globally approved for histiocytic disorders, with potential differentiation through its pediatric formulation and dosing flexibility
- Revenue Potential: Analysts estimate peak annual sales of ¥800–1.2 billion (US$110–165 million) across all indications by 2028, assuming 15–20% market penetration in addressable populations
Fosun Pharma’s continued investment in luvometinib’s clinical development reflects its strategy to build a diversified oncology portfolio targeting both common malignancies and rare histiocytic disorders with precision medicine approaches.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, clinical development timelines, and commercial expectations for Fumaining (luvometinib). Actual results may differ due to risks including final regulatory decisions, clinical trial outcomes, market adoption, and competitive dynamics.-Fineline Info & Tech